Highlights
- Postoperative initiation of GLP-1 receptor agonists (GLP-1RAs) after curative-intent liver resection for hepatocellular carcinoma (HCC) in patients with type 2 diabetes (T2D) reduces tumor recurrence risk and improves overall survival compared to dipeptidyl peptidase-4 inhibitors (DPP-4is).
- The largest target trial emulation to date involved 1249 patients from 36 hospitals in China, leveraging real-world electronic medical records for prolonged follow-up (median 50.8 months).
- GLP-1RAs may exert anti-tumor effects beyond glycemic control, suggesting actionable biological mechanisms influencing HCC progression and recurrence.
- Results from the observational emulation warrant prospective clinical trials to establish causality and guide clinical decision-making.
Background
Hepatocellular carcinoma (HCC) ranks among the leading causes of cancer mortality globally, with surgical resection offering a potential curative approach in selected patients. However, recurrence rates post-resection are high, substantially limiting long-term survival. Comorbid type 2 diabetes (T2D) is prevalent among HCC patients and independently portends poorer prognosis. Optimal postoperative management of T2D is critical, as glycemic control and choice of antidiabetic therapy may influence tumor biology and clinical outcomes.
Incretin-based therapies — principally glucagon-like peptide-1 receptor agonists (GLP-1RAs) and dipeptidyl peptidase-4 inhibitors (DPP-4is) — have transformed T2D management due to favorable glycemic effects and cardiovascular benefits. Emerging evidence indicates potential antineoplastic properties of GLP-1RAs in various cancers, possibly mediated through direct tumor-suppressive mechanisms or immunomodulation. Conversely, DPP-4is’ influence on cancer outcomes remains less clear.
This knowledge gap extends to the postoperative HCC setting, where whether incretin-based therapy choice impacts tumor recurrence or survival remains to be clarified.
Key Content
Chronological Development of Evidence on Incretin-Based Therapies and Cancer Outcomes
Early observational studies (circa 2010-2015) raised concerns regarding incretin-based agents and cancer risk. However, subsequent meta-analyses and randomized controlled trials (RCTs) from 2016 onwards largely dispelled these fears, with some data suggesting anticancer benefits of GLP-1RAs, especially in gastrointestinal malignancies.
Mechanistic preclinical studies have demonstrated that GLP-1RAs can inhibit tumor cell proliferation, induce apoptosis, and modulate the tumor microenvironment. Animal models of HCC treated with GLP-1RAs showed reduced tumor burden and delayed progression, supporting clinical investigations.
Evidence by Therapeutic Class and Clinical Context
– GLP-1 receptor agonists (GLP-1RAs): Several retrospective cohorts and post hoc analyses of cardiovascular outcome trials observed a lower incidence of certain cancers and improved survival in diabetic patients using GLP-1RAs, including signals in liver-related malignancies.
– DPP-4 inhibitors (DPP-4is): Although DPP-4is effectively control glycemia, their influence on tumor biology is ambiguous. Some studies conjectured that DPP-4 inhibition may facilitate tumor progression via immune modulation, but clinical data are inconsistent.
Prior to the present study, no large-scale comparative analyses specifically addressing postoperative HCC recurrence and survival according to GLP-1RA versus DPP-4i use existed.
Target Trial Emulation Study Design and Population
The referenced study by Xiang et al. (PMID: 42399086) used an active-comparator, new-user design to emulate a randomized trial framework within observational data, enhancing causal inference reliability. Data encompassed 42,855 patients with HCC and T2D undergoing liver resection from 2014 to 2023 across 36 Chinese hospitals, culminating in 1249 eligible patients initiating GLP-1RA (n=526) or DPP-4i (n=723) therapy within 90 days postop.
Patients received R0 resection (complete tumor removal) and were followed prospectively through October 2025 for recurrence-free survival (RFS) as the primary outcome, accounting for competing risk of death without recurrence, and overall survival (OS) as secondary.
Robust statistical methods including weighted intention-to-treat and per-protocol analyses controlled for confounders and adherence.
Major Findings
– GLP-1RA initiation was associated with a significantly longer RFS (cause-specific hazard ratio [HR] 0.80, 95% confidence interval [CI] 0.67-0.96, p=0.016).
– Overall survival was markedly improved in the GLP-1RA group compared to DPP-4i (HR 0.58, 95% CI 0.47-0.71, p<0.001).
– Per-protocol analyses focusing on sustained adherence yielded consistent directional outcomes, reinforcing treatment-effect robustness.
Mechanistic Insights and Translational Implications
Potential mechanisms whereby GLP-1RAs may delay HCC recurrence and prolong survival include:
– Direct antiproliferative and proapoptotic effects on hepatoma cells via GLP-1 receptor activation.
– Modulation of metabolic pathways, improving insulin sensitivity and reducing hepatic inflammation, thereby limiting tumor-promoting microenvironment.
– Influence on immune surveillance, enhancing antitumor immunity through interactions with immune checkpoints.
These pleiotropic effects differ from DPP-4is, which mainly increase endogenous incretin levels by inhibiting DPP-4 activity but may lack immune-stimulating action.
Expert Commentary
This elegant target trial emulation study provides compelling evidence that, among patients with T2D undergoing curative liver resection for HCC, postoperative GLP-1RA therapy confers superior recurrence-free and overall survival benefits compared with DPP-4i therapy.
The study addresses a significant clinical conundrum and leverages a large, multicenter dataset with rigorous analytic techniques mitigating confounding biases inherent in observational data.
Its findings align with growing preclinical and clinical evidence favoring GLP-1RAs’ oncologic advantages, adding a nuanced perspective to diabetes management in cancer patients.
Nonetheless, limitations exist:
– Despite sophisticated adjustments, residual confounding cannot be excluded.
– The study cohort is restricted to Chinese patients; ethnic and geographic applicability warrants evaluation.
– The absence of randomized trial data mandates cautious interpretation.
Current clinical guidelines for diabetes management in cancer settings do not yet incorporate distinctions based on antidiabetic agent impact on tumor outcomes. This study supports consideration of GLP-1RAs preferentially when clinically appropriate.
Future prospective RCTs specifically designed to test incretin-based therapies against oncological endpoints are essential to validate and extend these findings.
Conclusion
Postoperative initiation of GLP-1 receptor agonists compared to dipeptidyl peptidase-4 inhibitors after curative resection for hepatocellular carcinoma in type 2 diabetes patients may significantly delay tumor recurrence and improve long-term survival. Emerging mechanistic data highlight GLP-1RAs’ multidimensional actions beyond glycemic control that can favorably modulate tumor biology. While this target trial emulation provides robust real-world evidence, prospective trials are imperative to confirm these observations and inform therapeutic guidelines.
These insights emphasize the potential of integrating metabolic and oncologic management paradigms to optimize outcomes in this high-risk patient population.
References
- Xiang YJ, Liu ZH, Feng JK, et al. Glucagon-like peptide-1 receptor agonists versus dipeptidyl peptidase-4 inhibitors after liver resection for hepatocellular carcinoma in patients with type 2 diabetes: a target trial emulation study. Gut. 2026 Jul 3. PMID: 42399086.
- Nauck MA, Meier JJ. Incretin-Based Therapies: Biological Actions and Clinical Outcome. Adv Pharmacol. 2020;87:31-94. PMID: 33218252.
- Garber AJ. Incretin Therapeutics: Review of the Current Treatment Landscape and Future Developments. Diabetes Care. 2020;43(11):2567-2579. PMID: 32970994.
- Knapen LM, Stehouwer CDA, van der Kallen CJH, Schalkwijk CG. Incretin Therapies and Cancer Risk: Where Do We Stand? Trends Endocrinol Metab. 2021;32(9):661-673. PMID: 33911718.
- Lai WS, Chu CC, Yang F, et al. Effects of GLP-1 receptor agonists and DPP-4 inhibitors on cancer biology: preclinical and clinical perspectives. Front Pharmacol. 2021;12:655602. PMID: 33895535.
